13,992 Shares in Royalty Pharma PLC $RPRX Bought by Kestra Investment Management LLC

Kestra Investment Management LLC bought a new position in Royalty Pharma PLC (NASDAQ:RPRX) during the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 13,992 shares of the biopharmaceutical company’s stock, valued at approximately $541,000.

Other hedge funds and other institutional investors have also modified their holdings of the company. Lloyd Advisory Services LLC. acquired a new stake in shares of Royalty Pharma in the fourth quarter worth $30,000. Smartleaf Asset Management LLC raised its holdings in Royalty Pharma by 868.1% during the third quarter. Smartleaf Asset Management LLC now owns 881 shares of the biopharmaceutical company’s stock valued at $31,000 after buying an additional 790 shares in the last quarter. Private Trust Co. NA raised its holdings in Royalty Pharma by 52.9% during the fourth quarter. Private Trust Co. NA now owns 832 shares of the biopharmaceutical company’s stock valued at $32,000 after buying an additional 288 shares in the last quarter. Larson Financial Group LLC raised its holdings in Royalty Pharma by 31.9% during the third quarter. Larson Financial Group LLC now owns 1,264 shares of the biopharmaceutical company’s stock valued at $45,000 after buying an additional 306 shares in the last quarter. Finally, Fifth Third Bancorp increased its stake in shares of Royalty Pharma by 16.9% in the third quarter. Fifth Third Bancorp now owns 2,499 shares of the biopharmaceutical company’s stock worth $88,000 after purchasing an additional 362 shares during the period. Institutional investors and hedge funds own 54.35% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have recently commented on the company. Morgan Stanley lifted their price objective on Royalty Pharma from $61.00 to $63.00 and gave the stock an “overweight” rating in a research note on Friday, April 10th. The Goldman Sachs Group reaffirmed a “buy” rating on shares of Royalty Pharma in a report on Thursday, February 12th. Wall Street Zen raised Royalty Pharma from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. JPMorgan Chase & Co. boosted their price objective on Royalty Pharma from $50.00 to $58.00 and gave the stock an “overweight” rating in a research note on Thursday, May 7th. Finally, Citigroup lifted their price target on Royalty Pharma from $50.00 to $66.00 and gave the company a “buy” rating in a report on Thursday, May 7th. Seven research analysts have rated the stock with a Buy rating, According to MarketBeat.com, Royalty Pharma presently has an average rating of “Buy” and a consensus price target of $53.71.

Royalty Pharma Stock Performance

Shares of Royalty Pharma stock opened at $53.97 on Thursday. The company has a market capitalization of $31.08 billion, a PE ratio of 36.71, a PEG ratio of 1.48 and a beta of 0.40. Royalty Pharma PLC has a 12 month low of $32.29 and a 12 month high of $54.74. The company has a current ratio of 2.66, a quick ratio of 2.66 and a debt-to-equity ratio of 0.86. The stock’s fifty day simple moving average is $49.52 and its 200 day simple moving average is $44.27.

Royalty Pharma (NASDAQ:RPRX) last issued its quarterly earnings data on Wednesday, May 6th. The biopharmaceutical company reported $1.30 EPS for the quarter, topping the consensus estimate of $1.22 by $0.08. The business had revenue of $631.00 million for the quarter, compared to the consensus estimate of $881.69 million. Royalty Pharma had a return on equity of 29.25% and a net margin of 33.88%. On average, research analysts predict that Royalty Pharma PLC will post 5.05 EPS for the current year.

Royalty Pharma Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Wednesday, June 10th. Shareholders of record on Friday, May 15th will be issued a dividend of $0.235 per share. This represents a $0.94 dividend on an annualized basis and a yield of 1.7%. The ex-dividend date is Friday, May 15th. Royalty Pharma’s dividend payout ratio is 63.95%.

Insiders Place Their Bets

In other Royalty Pharma news, Director Gregory Norden sold 3,045 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.00, for a total transaction of $161,385.00. Following the completion of the transaction, the director owned 191,803 shares in the company, valued at approximately $10,165,559. This represents a 1.56% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Marshall Urist sold 13,684 shares of the stock in a transaction dated Thursday, May 14th. The stock was sold at an average price of $53.06, for a total value of $726,073.04. Following the transaction, the executive vice president owned 31,881 shares of the company’s stock, valued at approximately $1,691,605.86. This trade represents a 30.03% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders sold 169,577 shares of company stock worth $8,234,191. Corporate insiders own 18.84% of the company’s stock.

Royalty Pharma Company Profile

Royalty Pharma plc is a specialty finance company that acquires biopharmaceutical royalty interests and provides non-dilutive financing to drug developers and rights holders. The firm purchases future royalty streams, milestone-contingent payments and other revenue rights linked to approved and late-stage pharmaceutical and biotechnology products. By paying upfront consideration for these rights, Royalty Pharma seeks to generate long-term cash flows tied to the commercial performance of a diversified portfolio of medicines.

The company’s transaction structures include outright royalty purchases, structured financings and milestone arrangements tailored to the needs of innovator companies, academic institutions and investors.